SinoMab BioScience (HKSE:03681) FCF Margin % : -4,872.63% (As of Jun. 2024)

View and export this data going back to 2019. Start your Free Trial

What is SinoMab BioScience FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. SinoMab BioScience's Free Cash Flow for the six months ended in Jun. 2024 was HK$-106.27 Mil. SinoMab BioScience's Revenue for the six months ended in Jun. 2024 was HK$2.18 Mil. Therefore, SinoMab BioScience's FCF Margin % for the quarter that ended in Jun. 2024 was -4,872.63%.

As of today, SinoMab BioScience's current FCF Yield % is -19.03%.

The historical rank and industry rank for SinoMab BioScience's FCF Margin % or its related term are showing as below:

HKSE:03681' s FCF Margin % Range Over the Past 10 Years
Min: -17416.88 Med: -9406.89 Max: -1396.9
Current: -10573.31

During the past 7 years, the highest FCF Margin % of SinoMab BioScience was -1396.90%. The lowest was -17416.88%. And the median was -9406.89%.

HKSE:03681's FCF Margin % is ranked worse than
91.77% of 1045 companies
in the Biotechnology industry
Industry Median: -145.32 vs HKSE:03681: -10573.31

SinoMab BioScience FCF Margin % Historical Data

The historical data trend for SinoMab BioScience's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SinoMab BioScience FCF Margin % Chart

SinoMab BioScience Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-1,396.90

-17,416.88

SinoMab BioScience Semi-Annual Data
	Dec17	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
FCF Margin %	Get a 7-Day Free Trial								-	-	-9,089.22	-	-4,872.63

Competitive Comparison of SinoMab BioScience's FCF Margin %

For the Biotechnology subindustry, SinoMab BioScience's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SinoMab BioScience's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SinoMab BioScience's FCF Margin % distribution charts can be found below:

* The bar in red indicates where SinoMab BioScience's FCF Margin % falls into.

SinoMab BioScience FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

SinoMab BioScience's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-260.034	/	1.493
	=	-17,416.88 %

SinoMab BioScience's FCF Margin for the quarter that ended in Jun. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jun. 2024 )	/	Revenue (Q: Jun. 2024 )
	=	-106.272	/	2.181
	=	-4,872.63 %

SinoMab BioScience FCF Margin % Related Terms

Thank you for viewing the detailed overview of SinoMab BioScience's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

SinoMab BioScience Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SinoMab BioScience Ltd (HKSE:03681) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 15 Science Park West Avenue, Units 303 and 305 to 307, Hong Kong Science Park, Pak Shek Kok, New Territories, Hong Kong, HKG

Website

https://www.sinomab.com

SinoMab BioScience Ltd is a biopharmaceutical company. The company is engaged in the research, development, manufacturing, and commercialization of therapeutics for the treatment of immunological diseases, monoclonal antibody (mAb)-based biologics. Its flagship product, SM03 (Suciraslimab), is a potential global first-in target mAb for the treatment of rheumatoid arthritis (RA) and potentially for the treatment of other immunological diseases such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS) as well as non-Hodgkin's lymphoma (NHL), and other indications. The group derives revenue from Hong Kong.

Executives

Hainan Haiyao Co. Ltd.	2101 Beneficial owner
Liu Wenyi	2201 Interest of corporation controlled by you
Leung Shui On	2201 Interest of corporation controlled by you
Qiang Jing
West Biolake Holdings Limited	2101 Beneficial owner
Skytech Technology Limited	2101 Beneficial owner
China Citic Bank Co., Ltd., Haikou Branch	2106 Person having a security interest in shares
Xu Sijia	2101 Beneficial owner
Hai Kou Shi Nong Cun Xin Yong He Zuo Lian She	2106 Person having a security interest in shares
Apricot Oversea Holdings Limited	2101 Beneficial owner
Yun Nan Bai Yao Ji Tuan Gu Fen You Xian Gong Si	2101 Beneficial owner
Shang Hai Yue Yi Tou Zi Zhong Xin You Xian He Huo	2201 Interest of corporation controlled by you
Shang Hai Xing Ze Tou Zi Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
Hai Nan Hai Yao Gu Fen You Xian Gong Si	2101 Beneficial owner

SinoMab BioScience Headlines

No Headlines